Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD.

[1]  E. Kerwin,et al.  Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model , 2021, International journal of chronic obstructive pulmonary disease.

[2]  E. Kerwin,et al.  Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial , 2021, Respiratory Research.

[3]  E. Kerwin,et al.  Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial , 2021, Advances in Therapy.

[4]  E. Kerwin,et al.  Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial , 2021, International journal of chronic obstructive pulmonary disease.

[5]  E. Kerwin,et al.  Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement , 2021, International journal of chronic obstructive pulmonary disease.

[6]  I. Gilbert,et al.  Real-World Patterns and Implications of Short-Acting Beta2-Agonist Use in Patients with Asthma in the USA. , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  E. Kerwin,et al.  Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial , 2020, Therapeutic advances in respiratory disease.

[8]  P. Jones,et al.  Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial , 2020, Respiratory Research.

[9]  E. Kerwin,et al.  Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial , 2020, Therapeutic advances in respiratory disease.

[10]  J. Wedzicha,et al.  Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[11]  R. Knaggs,et al.  Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review , 2020, BMJ Open.

[12]  C. Janson,et al.  Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme , 2020, European Respiratory Journal.

[13]  J. Cockcroft,et al.  Daily physical activity and related risk factors in COPD , 2019, BMC Pulmonary Medicine.

[14]  E. Kerwin,et al.  Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial , 2019, Respiratory Research.

[15]  M. Beauchesne,et al.  Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence , 2019, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.

[16]  L. Tombs,et al.  Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis , 2019, Respiratory Research.

[17]  F. Blasi,et al.  Administrative databases and clinical governance: The case of COPD , 2019, The International journal of health planning and management.

[18]  J. Soriano,et al.  What is early COPD and why is it important? , 2018, European Respiratory Journal.

[19]  P. Jones,et al.  Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. , 2018, Pulmonary pharmacology & therapeutics.

[20]  E. Horváth-Puhó,et al.  Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. , 2018, The Lancet. Respiratory medicine.

[21]  J. Riley,et al.  Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study , 2017, Advances in Therapy.

[22]  A. Ismaila,et al.  A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD , 2017, Pulmonary Therapy.

[23]  D. Postma,et al.  The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials , 2017, International journal of chronic obstructive pulmonary disease.

[24]  A. Ismaila,et al.  Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  M. Miravitlles,et al.  Understanding the impact of symptoms on the burden of COPD , 2017, Respiratory Research.

[26]  D. Coultas.  Physical Inactivity, Self-Management, and Living Well With COPD , 2017, American journal of lifestyle medicine.

[27]  Reiner Leidl,et al.  External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  A. Anzueto,et al.  Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials , 2016, Advances in Therapy.

[29]  Huong Q. Nguyen,et al.  Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability. , 2016, Respiratory medicine.

[30]  Dave Singh,et al.  Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol , 2016, International journal of chronic obstructive pulmonary disease.

[31]  M. Cazzola,et al.  COPD : the patient perspective , 2016 .

[32]  Nobhojit Roy,et al.  Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition , 2015, The Lancet.

[33]  S. Dias,et al.  Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis , 2015, Thorax.

[34]  A. Ismaila,et al.  Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis , 2015, International journal of chronic obstructive pulmonary disease.

[35]  D. Postma,et al.  Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease , 2015, BMC Pulmonary Medicine.

[36]  C. Vogelmeier,et al.  COPD: early diagnosis and treatment to slow disease progression , 2015, International journal of clinical practice.

[37]  E. Kerwin,et al.  Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[38]  L. Edwards,et al.  Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort , 2013, European Respiratory Journal.